Meeting Report

Hematologic Malignancies: 2022 ASCO Annual Meeting Highlights for the Advanced Practitioner

P. Andrew Allred, MS, PA-C, Amy Pierre, MSN, ANP-BC, Meredith Beaton, MSN, RN, Pamela Lee, NP, MSN, and Amber Koehler, PA-C


J Adv Pract Oncol 2022;13(6):618-632 | https://doi.org/10.6004/jadpro.2022.13.6.9 | Ā© 2022 Harborsideā„¢


  

ABSTRACT

P. Andrew Allred, MS, PA-C, of Banner MD Anderson Cancer Center, considers data on managing newly diagnosed MM and CAR T-cell therapy in MM. Amy Pierre, MSN, ANP-BC, of MSKCC and Flatiron Health, reviews findings on telemedicine inequities and real-world data on axicabtagene ciloleucel. Meredith Beaton, MSN, RN, of UCHealth, evaluates data on FLT3-mutated AML and TKI discontinuation in CML. Pamela Lee, NP, MSN, of UCSF Medical Center, analyzes results of a new BiTE therapy in DLBCL and CAR T-cell therapy in MCL. Amber Koehler, PA-C, of Mayo Clinic Cancer Center, reviews combination therapies for CLL.




For access to the full length article, please sign in.

Section Seperator
ADVERTISEMENT
Section Seperator
ADVERTISEMENT
Section Seperator
ADVERTISEMENT
Section Seperator
Copyright © 2010-2022 Harborside Press, LLC All rights reserved.               
Home | Current Issue | Previous Issue | Submissions | About JADPRO | Advertising | Privacy Policy | Contact | Copyright Notice/Disclaimer | Subscribe
Bot trap - Don't go here
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.